Working… Menu

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02834013
Recruitment Status : Suspended (Other - Pending revision to increase accrual target)
First Posted : July 15, 2016
Last Update Posted : November 25, 2019
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : January 9, 2024
Study Completion Date : No date given